VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB111 in Recurrent Glioblastoma rGBM at the ECC 2015 Conference Meeting the Primary Endpoint of StatisticallySignificant Increase in Overall Survival

Press/Media: Press / Media

PeriodSep 28 2015

Media coverage

1

Media coverage

  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB111 in Recurrent Glioblastoma rGBM at the ECC 2015 Conference Meeting the Primary Endpoint of StatisticallySignificant Increase in Overall Survival
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date9/28/15
    PersonsAndrew Brenner